Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 105.17% | 128.99% | 146.71% | 182.44% | 254.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.17% | 128.99% | 146.71% | 182.44% | 254.45% |
| Cost of Revenue | 54.56% | 26.94% | 19.94% | 22.59% | 12.45% |
| Gross Profit | 118.89% | 174.53% | 218.61% | 315.71% | 750.76% |
| SG&A Expenses | 67.15% | 76.84% | 80.07% | 73.07% | 71.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.39% | 70.89% | 72.09% | 67.83% | 64.16% |
| Operating Income | 50.50% | 53.45% | 41.14% | 37.83% | 37.30% |
| Income Before Tax | 57.23% | 58.21% | 44.30% | 39.59% | 38.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.48% | 54.01% | 42.52% | 39.59% | 38.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.48% | 54.01% | 42.52% | 39.59% | 38.70% |
| EBIT | 50.50% | 53.45% | 41.14% | 37.83% | 37.30% |
| EBITDA | 52.09% | 54.51% | 42.06% | 38.61% | 37.90% |
| EPS Basic | 53.58% | 58.45% | 48.11% | 47.21% | 48.06% |
| Normalized Basic EPS | 60.74% | 64.03% | 49.93% | 46.92% | 47.78% |
| EPS Diluted | 53.58% | 58.45% | 48.11% | 47.21% | 48.06% |
| Normalized Diluted EPS | 60.74% | 64.03% | 49.93% | 46.92% | 47.78% |
| Average Basic Shares Outstanding | 8.25% | 10.77% | 11.35% | 13.54% | 16.92% |
| Average Diluted Shares Outstanding | 8.25% | 10.77% | 11.35% | 13.54% | 16.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |